Animal study · mice
Retatrutide: 14-fold smaller pancreatic tumors in mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
Early animal work links retatrutide-driven weight loss to slower pancreatic and lung tumor growth, but it says nothing yet about cancer in people.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2025
- Journal
- NPJ Metab Health Dis
What they tested
The team tested whether weight loss from retatrutide changes how obesity-associated cancers take hold and grow in preclinical models.
How the study was done
A preclinical study in a mouse pancreatic cancer model and a lung cancer model, with retatrutide causing significant weight loss. Retatrutide was compared with controls and, in the pancreatic model, with semaglutide, a single agonist.

Model. Individual results vary.
What they found
In mice with pancreatic cancer, retatrutide led to fewer tumors taking hold (engraftment), later tumor onset and slower growth. Tumor volume fell 14-fold, compared with a 4-fold drop in semaglutide-treated mice, and the benefit held even after retatrutide was stopped and weight came back. In the lung cancer model, tumor engraftment was 50% lower, onset came significantly later, and tumor volume was 17-fold smaller than in controls. The animals also showed immune changes, including higher IL-6 in the blood, more antigen-presenting cells (immune cells that flag threats) and fewer immune-suppressing cells.
What it doesn’t show
This was done only in preclinical animal models, so it is not a human result. It did not test whether retatrutide lowers cancer risk or improves cancer outcomes in people.
The paper
Marathe et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.